Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).

Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME.

Support Care Cancer. 2013 Apr;21(4):1033-41. doi: 10.1007/s00520-012-1623-4. Epub 2012 Nov 7.

PMID:
23128934
2.

Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.

Boucher J, Olson L, Piperdi B.

Clin J Oncol Nurs. 2011 Oct;15(5):501-8. doi: 10.1188/11.CJON.501-508.

PMID:
21951736
4.

Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.

Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA.

Eur J Oncol Nurs. 2013 Dec;17(6):802-7. doi: 10.1016/j.ejon.2013.03.004. Epub 2013 Apr 6.

PMID:
23571183
5.

Clinical management of EGFRI dermatologic toxicities: US perspective.

Lacouture ME, Cotliar J, Mitchell EP.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21.

6.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A.

Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10.

PMID:
20145956
7.

Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events.

Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA.

Support Care Cancer. 2013 Jul;21(7):1919-26. doi: 10.1007/s00520-013-1752-4. Epub 2013 Feb 17.

PMID:
23417565
8.

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

Tan EH, Chan A.

Ann Pharmacother. 2009 Oct;43(10):1658-66. doi: 10.1345/aph.1M241. Epub 2009 Sep 15. Review.

PMID:
19755624
9.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
11.

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME.

J Natl Cancer Inst. 2010 Jan 6;102(1):47-53. doi: 10.1093/jnci/djp439. Epub 2009 Dec 9.

PMID:
20007525
12.

Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

Amitay-Laish I, David M, Stemmer SM.

Oncologist. 2010;15(9):1002-8. doi: 10.1634/theoncologist.2010-0063. Epub 2010 Aug 13.

13.

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME.

Oncologist. 2007 May;12(5):610-21. Review.

14.

Xerosis and pruritus as major EGFRI-associated adverse events.

Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, Kaptein AA.

Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.

15.

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C.

Br J Dermatol. 2009 Sep;161(3):515-21. doi: 10.1111/j.1365-2133.2009.09214.x. Epub 2009 Apr 10.

PMID:
19466958
16.

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.

Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guérin A.

J Med Econ. 2013;16(2):221-30. doi: 10.3111/13696998.2012.749789. Epub 2012 Nov 27.

PMID:
23153319
17.

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME.

Cancer. 2010 Aug 15;116(16):3916-23. doi: 10.1002/cncr.25090.

18.

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

Wu PA, Balagula Y, Lacouture ME, Anadkat MJ.

Curr Opin Oncol. 2011 Jul;23(4):343-51. doi: 10.1097/CCO.0b013e3283474063. Review.

PMID:
21537180
19.

Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.

White KJ, Roydhouse JK, Scott K.

Clin J Oncol Nurs. 2011 Feb;15(1):88-96. doi: 10.1188/11.CJON.88-96. Review.

PMID:
21278044
20.

Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.

Yamazaki N, Muro K.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):27-8.

Supplemental Content

Support Center